Figure 3
![Figure 3. Survival rates. Compared with MDS/MPN-U, patients with aCML showed a significant inferior OS (12.4 months, 95% CI [9.0-16.1] vs 21.8 months, 95% CI [17.6-28.8]) and ACL-free survival (11.2 months, 95% CI [7.0-13.5] vs 18.9 months, 95% CI [12.3-26.3]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/123/17/10.1182_blood-2014-02-553800/4/2645f3.jpeg?Expires=1722439870&Signature=D~3T6HHWBUSj7kWfqkqeC5iCD7AZfdIix0HzfcUIBGOjYiptmc2vyepcPOyZAOIBJQFhP0LU2A5QCVqz3AF2SQpWOpRLqf709dnpLZOy21y-NDkwOLSPZXCyyVx8cSqbJOPXVvjP6yKd384Q1LzeJymLjKbXNtsVUu6e2L9hvwtnUtE-OjK2NUGIFxQEAbktmqTO4bd68fseBGtCQzXUfLjhtvn91SBMwvwBaALOTOSMMIQK6e0m7-cXCqloIP1-z6Lzi4VnFQJPt0NWNX4yfSu-Os-1Ie6of5XL3ieaDRGtC7xj-RDds7yd2BFNZd2KHwnrMbgP5mLqkVMpr-2-oA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival rates. Compared with MDS/MPN-U, patients with aCML showed a significant inferior OS (12.4 months, 95% CI [9.0-16.1] vs 21.8 months, 95% CI [17.6-28.8]) and ACL-free survival (11.2 months, 95% CI [7.0-13.5] vs 18.9 months, 95% CI [12.3-26.3]).
